World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
29522
World Ranking
15480
National Ranking
1426

Overview

Peter C. Taylor is affiliated with the University of Oxford in the United Kingdom and specializes in the field of Medicine, with a primary focus on Rheumatology. Their research portfolio includes a substantial number of publications in this subfield, supported by additional expertise in Hematology, Genetics, Immunology, and Pathology and Forensic Medicine.

The research work of Peter C. Taylor predominantly addresses topics related to Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, and Chronic Lymphocytic Leukemia Research. Other notable topics include Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, Lymphoma Diagnosis and Treatment, and Cytokine Signaling Pathways and Interactions.

Among their recent published papers are:

  • Neutralizing monoclonal antibodies for treatment of COVID-19, 2021, published in Nature reviews. Immunology
  • Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database, 2021, published in Annals of the Rheumatic Diseases

Peter C. Taylor has collaborated frequently with a community of researchers active in related fields. Frequent co-authors include Tsutomu Takeuchi, Yoshiya Tanaka, Ewa Haładyj, Bruno Fautrel, and Gerd R Burmester.

Their publications have been featured most often in the following venues:

  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • Endocrine Abstracts
  • Rheumatology and Therapy
  • RMD Open

These journals highlight a consistent involvement in rheumatology and related clinical therapeutic research domains.

Best Publications

  • Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events.

    F D Loop;B W Lytle;D M Cosgrove;R W Stewart

  • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

    R N Maini;P C Taylor;J Szechinski;K Pavelka

  • Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

    Peter C. Taylor;Edward C. Keystone;Désirée van der Heijde;Michael E. Weinblatt

  • Neutralizing monoclonal antibodies for treatment of COVID-19.

    Peter C. Taylor;Andrew C. Adams;Matthew M. Hufford;Inmaculada de la Torre

  • Anti-TNF therapy: past, present and future

    Claudia Monaco;Jagdeep Nanchahal;Peter Taylor;Marc Feldmann

  • Anti-cytokine therapy for rheumatoid arthritis.

    R N Maini;P C Taylor

  • Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.

    Peter C. Taylor;Marc Feldmann

  • Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

    X Mariette;M Matucci-Cerinic;K Pavelka;P Taylor

  • Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.

    P P Tak;P C Taylor;F C Breedveld;T J Smeets

  • Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

    P C Taylor;A M Peters;E Paleolog;P T Chapman

  • Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis.

    Andrew Kinloch;Verena Tatzer;Robin Wait;David Peston

  • Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis†

    P. C. Taylor;A. Steuer;J. Gruber;D. O. Cosgrove

  • Diagnosis and management of acute graft-versus-host disease.

    Fiona L. Dignan;Andrew Clark;Persis Amrolia;Jacqueline Cornish

  • Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes

    Myles J. Lewis;Michael R. Barnes;Michael R. Barnes;Kevin Blighe;Katriona Goldmann

  • Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.

    Sundeept Ballara;Peter C. Taylor;Petra Reusch;Dieter Marmé

  • The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

    Andreas Reiter;Christoph Walz;Ann Watmore;Claudia Schoch

  • Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

    Edward C Keystone;Peter C Taylor;Edit Drescher;Douglas E Schlichting

  • Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.

    Ravinder N. Maini;Michael J. Elliott;Fionula M. Brennan;Richard O. Williams

  • Human neutrophils secrete vascular endothelial growth factor.

    Norton S. Taichman;Sylvia Young;Alan T. Cruchley;Peter Taylor

  • A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective.

    Peter C. Taylor;Adam Moore;Radu Vasilescu;Jose Alvir

Frequent Co-Authors

Iain B. McInnes
Iain B. McInnes University of Glasgow
Christopher D. Buckley
Christopher D. Buckley University of Oxford
Paul Emery
Paul Emery University of Leeds
Marc Feldmann
Marc Feldmann University of Oxford
Costantino Pitzalis
Costantino Pitzalis Queen Mary University of London
Michele Bombardieri
Michele Bombardieri Queen Mary University of London
Mark C. Genovese
Mark C. Genovese Stanford University
Ravinder N. Maini
Ravinder N. Maini Imperial College London
Ewa M. Paleolog
Ewa M. Paleolog University of Oxford
Richard O. Williams
Richard O. Williams University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending traditional, in-person programs. Today, there are a variety of online degree options and career pathways that can help you advance or change your role within healthcare—even from home.

Nurses looking to move up often consider bridge programs. For example, if you’re already an RN, pursuing an rn to bsn online with no clinicals can save time and fit into a busy work schedule. Those aiming even higher may look at advanced roles through the fastest dnp program or search for the cheapest online dnp programs to gain a doctorate in nursing with less financial burden.

Additionally, learners can enter the medical field quickly through options like a fast track lpn, which can lead to practical nursing jobs in less time than traditional programs.

Online healthcare programs can be flexible, accelerated, and affordable—but students should consider accreditation, program requirements, and career goals before enrolling. These options open new doors for anyone passionate about making a difference in medicine.

Best Scientists Citing Peter C. Taylor

Trending Scientists